Computational chemistry

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

Retrieved on: 
Wednesday, September 7, 2022
AbbVie, ISIN, Chronic liver disease, CEO, Pharmacokinetics, Research, Degenerative disease, Nasdaq, Fatty liver disease, Factor X, Computational chemistry, MPS, IVA, Pharmacology, Biology, Company, Mucopolysaccharidosis, NASH, VI, Adult, Q&A, Patient, Pharmaceutical industry, Euronext Paris

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/v5uzhkr8 and also available on Inventivas onwards in the Investors Financial results section.

Key Points: 

Ventus Therapeutics Opens New Facility in Waltham, MA as First Phase of Global Expansion

Retrieved on: 
Tuesday, September 6, 2022
Health, Neurology, Other Health, Research, Science, Pharmaceutical, Biotechnology, Inflammation, DMPK, COVID-19, Workforce, NLRP3, CEO, Therapy, Resolve, Molecular biology, Computational chemistry, LinkedIn, Laboratory, Neurology, Pain scale, Company, Biochemistry, Industry, Health, Fine chemical, Ventus

This new facility augments Ventus existing 10,000-square-foot facility in Montreal, which houses Ventus drug discovery and development organization, including its medicinal chemistry, computational chemistry, DMPK, and disease biology teams.

Key Points: 
  • This new facility augments Ventus existing 10,000-square-foot facility in Montreal, which houses Ventus drug discovery and development organization, including its medicinal chemistry, computational chemistry, DMPK, and disease biology teams.
  • The second phase of Ventus global expansion includes doubling the companys footprint in Montreal with the planned opening of a new 23,000-square-foot facility in 2023 to further support the expansion of ReSOLVE and Ventus pipeline programs.
  • As an end-to-end drug discovery platform, ReSOLVE allows Ventus to advance novel differentiated small molecules in a much more time- and cost-efficient manner than conventional drug discovery approaches.
  • For more information, please visit www.ventustx.com and engage with Ventus on Twitter @Ventus_Tx or on LinkedIn.

TandemAI Announces Appointment of Steve Swann, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, August 25, 2022
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, AbbVie, Partnership, University, CEO, Technology, Research, Takeda Pharmaceutical Company, Therapy, DuPont (1802–2017), US, Computational chemistry, MBA, Saint Francis University, Intelligence, Silicon, Medicinal chemistry, Drug discovery, Industry, Pharmaceutical industry, Fine chemical, Chemistry

TandemAI today announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer.

Key Points: 
  • TandemAI today announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer.
  • Steve is a leader in integrating advanced computational methods with medicinal chemistry for small molecule drug design who brings an outstanding track record in drug discovery, said Jeff He, MBA, TandemAIs co-founder and CEO.
  • He has been instrumental to bringing multiple drugs from discovery into clinical trials, two of which are marketed.
  • With his addition to our team, we are well positioned to serve the drug discovery needs of our rapidly growing client base.

Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting

Retrieved on: 
Wednesday, August 24, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Janus, HPK1, Inflammation, Research, Degenerative disease, Therapy, Autoimmunity, Protein, Pathology, Computational chemistry, Senior, Lists of diseases, Psoriasis, Janus kinase, Leadership, TYK2, Nimbus, JAK, American Chemical Society, ClinicalTrials.gov, Pharmaceutical industry, Vaccine, Fine chemical, Chemistry

The data, presented in an oral session at the American Chemical Society Fall 2022 meeting, describe how Nimbus leveraged structural biology and computational chemistry insights to produce a novel TYK2 inhibitor with a potential best-in-class profile with respect to potency, selectivity and optimized pharmacokinetics/pharmacodynamics properties.

Key Points: 
  • The data, presented in an oral session at the American Chemical Society Fall 2022 meeting, describe how Nimbus leveraged structural biology and computational chemistry insights to produce a novel TYK2 inhibitor with a potential best-in-class profile with respect to potency, selectivity and optimized pharmacokinetics/pharmacodynamics properties.
  • Development focused on maximizing the small molecules therapeutic benefit by achieving highly selective inhibition of the pseudokinase JH2 domain of TYK2.
  • Notably, it has been shown in cellular assays to be significantly more selective than Bristol Myers Squibbs TYK2 inhibitor deucravacitinib.
  • Nimbus Therapeutics is a clinical-stage company working to design and develop breakthrough medicines through its powerful and comprehensive computational drug discovery engine.

Inventiva Reports 2022 First-Half Financial Information¹

Retrieved on: 
Thursday, July 28, 2022
Nasdaq, VI, Pharmacology, Obesity, Documentation, MPS, PGE, Computational chemistry, ISIN, Dijon, AASLD, Research, IVA, Lyon, NASH, Mucopolysaccharidosis, Adult, USD, European Investment Bank, Conference, Financial result, AbbVie, EIB, Chronic liver disease, Company, Patient, Psoriasis, Factor X, Pharmacokinetics, Degenerative disease, Biology, Drug development, Fatty liver disease, Pharmaceutical industry, Renewable energy, Bank, Airline, Nightclub, Euronext Paris

As of June 30, 2022, Inventivas cash position was 87.2 million compared to 80.5 million as of March 31, 2022 and 95.4 million as of December 31, 2021.

Key Points: 
  • As of June 30, 2022, Inventivas cash position was 87.2 million compared to 80.5 million as of March 31, 2022 and 95.4 million as of December 31, 2021.
  • Net cash used in operating activities amounted to 26.1 million in the first half of 2022 compared to 19.8 million for the same period in 2021.
  • R&D expenses for the first half of 2022, mainly driven by the development of lanifibranor in NASH, were up 53% compared to the first half of 2021.
  • Net cash generated from investing activities for the first half of 2022 amounted to 0.8 million, compared to -1.2 million for the same period in 2021.

Quantinuum Expands Collaboration with JSR to Explore Quantum Computing for Semiconductor Research

Retrieved on: 
Wednesday, July 13, 2022
Method, Honeywell, DMFT, JSR, Solution, Science, Environment, Chemistry, CEO, Materials science, Algorithm, Computer, Computational chemistry, Research, Health, Climate change, Cambridge Quantum Computing, Software, Industry, Risk management, Microscope

TOKYO and CAMBRIDGE, England, July 13, 2022 /PRNewswire/ -- Quantinuum, the world's leading integrated quantum computing company, has announced a global collaboration with materials technology leader JSR Corporation of Japan to explore the application of quantum computing methods in semiconductor research.

Key Points: 
  • The collaboration will include the use of Quantinuum's Model H1 hardware, Powered by Honeywell, and InQuanto, its computational quantum chemistry software platform, to model complex organic and inorganic semiconductor materials
    TOKYO and CAMBRIDGE, England, July 13, 2022 /PRNewswire/ -- Quantinuum, the world's leading integrated quantum computing company, has announced a global collaboration with materials technology leader JSR Corporation of Japan to explore the application of quantum computing methods in semiconductor research.
  • The collaboration brings together JSR's world-leading materials scientists with quantum computing experts at Quantinuum in Japan, Europe, and the USA.
  • The Quantinuum team continues to lead the field in quantum computing hardware and software, complementing our scientists' deep expertise in materials innovation.
  • As a recognized leader in quantum computing, Quantinuum has active collaborations with industrial partners across automotive, chemicals, pharmaceutical and energy.

Quantinuum Expands Collaboration with JSR to Explore Quantum Computing for Semiconductor Research

Retrieved on: 
Wednesday, July 13, 2022
Method, Honeywell, DMFT, JSR, Solution, Science, Environment, Chemistry, CEO, Materials science, Algorithm, Computer, Computational chemistry, Research, Health, Climate change, Cambridge Quantum Computing, Software, Industry, Risk management, Microscope

TOKYO and CAMBRIDGE, England, July 13, 2022 /PRNewswire/ -- Quantinuum, the world's leading integrated quantum computing company, has announced a global collaboration with materials technology leader JSR Corporation of Japan to explore the application of quantum computing methods in semiconductor research.

Key Points: 
  • The collaboration will include the use of Quantinuum's Model H1 hardware, Powered by Honeywell, and InQuanto, its computational quantum chemistry software platform, to model complex organic and inorganic semiconductor materials
    TOKYO and CAMBRIDGE, England, July 13, 2022 /PRNewswire/ -- Quantinuum, the world's leading integrated quantum computing company, has announced a global collaboration with materials technology leader JSR Corporation of Japan to explore the application of quantum computing methods in semiconductor research.
  • The collaboration brings together JSR's world-leading materials scientists with quantum computing experts at Quantinuum in Japan, Europe, and the USA.
  • The Quantinuum team continues to lead the field in quantum computing hardware and software, complementing our scientists' deep expertise in materials innovation.
  • As a recognized leader in quantum computing, Quantinuum has active collaborations with industrial partners across automotive, chemicals, pharmaceutical and energy.

REAL LEADERS®️ UNVEILS ITS INAUGURAL ECO INNOVATION AWARD WINNERS

Retrieved on: 
Wednesday, July 6, 2022
Recycling, Transport, CEO, Achievement, Climate, Classification, IPCC, Computational chemistry, Organic, Barnes & Noble, United Nations Global Compact, Environment, Real, Health, Solution, Chemistry, Safety, Creativity, Social media, Management

AUSTIN, Texas and BOULDER, Colo. , July 6, 2022 /PRNewswire/ -- Smarter Sorting (www.smartersorting.com), a consumer goods data and sustainability company, has been announced as a Top 50 winner in the 2022 Real Leaders® Eco Innovation Awards. Smarter Sorting helps retailers and suppliers know more about regulated consumer products to make, market and move them across the supply chain more sustainably.

Key Points: 
  • This week,Real Leaders released its inaugural Eco Innovation Awards to its global community of social impact executives.
  • All winners will be featured in the Q3 2022 issue of Real Leaders magazine, on Real-Leaders.com, and will be promoted across social media.
  • Real Leaders is a membership community for impact leaders with a global media platform dedicated to driving positive change.
  • Real Leaders is a B Corporation, member of the UN Global Compact, and is independently owned.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas  , June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.